GFAP and Alzheimer disease: To test this hypothesis, we performed immunohistochemical staining in post-mortem human brains for FMNL2 and GFAP (Fig. 6) (control, AD, Primary age-related Tauopathy [PART] with or without cardiovascular pathology, Tables S12 and S13).